- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02897219
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
5 mars 2019 uppdaterad av: Astellas Pharma Inc
Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
The objective of this study is to confirm efficacy of ASP1941 based on the changes in HbA1c and to assess its safety in subjects with type 1 diabetes mellitus receiving ASP1941 once daily in combination with insulin for 24 weeks.
This study will also assess the safety/efficacy of long-term treatment (52 weeks).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study consists of two parts.
In Part 1, ASP1941 or placebo will be administered orally in a blind manner.
In Part 2, the long-term safety and efficacy of ASP1941 will be evaluated in patients who have participated in the study and completed the Part 1.
Studietyp
Interventionell
Inskrivning (Faktisk)
175
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Aichi, Japan
- Site JP00005
-
Aichi, Japan
- Site JP00028
-
Chiba, Japan
- Site JP00003
-
Chiba, Japan
- Site JP00013
-
Chiba, Japan
- Site JP00035
-
Fukuoka, Japan
- Site JP00023
-
Fukuoka, Japan
- Site JP00022
-
Fukuoka, Japan
- Site JP00031
-
Gunma, Japan
- Site JP00011
-
Gunma, Japan
- Site JP00002
-
Hiroshima, Japan
- Site JP00006
-
Hokkaido, Japan
- Site JP00033
-
Hokkaido, Japan
- Site JP00034
-
Hyogo, Japan
- Site JP00021
-
Ibaraki, Japan
- Site JP00009
-
Ibaraki, Japan
- Site JP00010
-
Kanagawa, Japan
- Site JP00004
-
Kanagawa, Japan
- Site JP00015
-
Kanagawa, Japan
- Site JP00016
-
Mie, Japan
- Site JP00019
-
Nagasaki, Japan
- Site JP00008
-
Nagasaki, Japan
- Site JP00024
-
Nagasaki, Japan
- Site JP00025
-
Nagasaki, Japan
- Site JP00032
-
Niigata, Japan
- Site JP00026
-
Osaka, Japan
- Site JP00036
-
Osaka, Japan
- Site JP00029
-
Osaka, Japan
- Site JP00020
-
Saitama, Japan
- Site JP00012
-
Shizuoka, Japan
- Site JP00018
-
Shizuoka, Japan
- Site JP00017
-
Tochigi, Japan
- Site JP00001
-
Tokushima, Japan
- Site JP00030
-
Tokyo, Japan
- Site JP00014
-
Toyama, Japan
- Site JP00027
-
Yamaguchi, Japan
- Site JP00007
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
20 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- The subject has been diagnosed with type 1 diabetes mellitus
- The subject has been receiving insulin therapy for the treatment of diabetes mellitus.
- The subject has not switched from an insulin product to another insulin product or switched between continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI).
- The subject has an HbA1c value between 7.5% and 11.0% and the difference of HbA1c value is within ± 2.0%.
- The subject has a fasting blood C-peptide level < 0.6 ng/mL.
- The subject has a body mass index (BMI) between 20.0 kg/m2 and 35.0 kg/m2.
Exclusion Criteria:
- The subject has type 2 diabetes mellitus.
- The subject has participated in a clinical study or post marketing study of another drug or medical equipment within 12 weeks (84 days) before providing written informed consent, or is currently participating in such a study.
- The subject has received treatment with ASP1941 (ipragliflozin) or participated in a clinical study of ASP1941 (excluding subjects who discontinued before the investigational period).
- The subject participated in this study previously.
- The subject has received a hypoglycemic agent other than insulin or an α-glucosidase inhibitor.
- The subject has proliferative retinopathy (except for those who have undergone photocoagulation etc. and whose symptoms are stable).
- The subject has experienced severe hypoglycemia.
- The subject has experienced diabetic ketoacidosis.
- The subject has chronic disease that requires the continuous use of corticosteroids, immunosuppressants, etc.
- The subject has symptomatic urinary tract infection or symptomatic genital infection.
- The subject has a history of recurrent urinary tract infection or recurrent genital infection.
- The subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, or another serious heart disease.
- The subject has a concomitant malignant tumor or a history of malignant tumor
- The subject has a history of an allergy to ASP1941 (ipragliflozin) and/or similar drugs (drugs possessing SGLT2 inhibitory action).
- The subject has psychiatric disorder that is inappropriate for participation in the study.
- The subject has drug addiction or alcohol abuse.
- The subject has severe infection or serious trauma, or is perioperative.
- The subject has a history of medically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant.
- The subject has any symptoms of dysuria, anuria, oliguria, or urinary retention.
- The subject has severe renal impairment or end-stage renal failure requiring dialysis.
- The subject has an Aspartate Aminotransferase and/or Alanine Aminotransferase value that exceeds 2 times, or a total bilirubin value that exceeds 1.5 times the upper limit of the reference range.
- The subject has uncontrolled severe hypertension.
- The subject has serious gastrointestinal disease or a history of operation for serious gastrointestinal disease.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1 ASP1941
ASP1941 will be administered for 24 weeks under double blind conditions.
|
Oral administration once daily
Andra namn:
Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
|
|
Placebo-jämförare: Part 1 Placebo
Placebo will be administered for 24 weeks under double blind conditions.
|
Oral administrering en gång dagligen
Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
|
|
Experimentell: Part 2 ASP1941
ASP1941 will be administered for 28 weeks under open label conditions.
|
Oral administration once daily
Andra namn:
Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change from baseline in HbA1c
Tidsram: Baseline and Week 24 (end of treatment period 1)
|
Baseline and Week 24 (end of treatment period 1)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Säkerheten bedöms utifrån förekomsten av biverkningar
Tidsram: Fram till vecka 56
|
Fram till vecka 56
|
|
|
Change from baseline in HbA1c
Tidsram: Baseline and up to Week 56
|
Baseline and up to Week 56
|
|
|
Change from baseline in Fasting plasma glucose
Tidsram: Baseline and up to Week 56
|
Baseline and up to Week 56
|
|
|
Change from baseline in self-monitored blood glucose level
Tidsram: Baseline and up to Week 56
|
Baseline and up to Week 56
|
|
|
Change from baseline in leptin
Tidsram: Baseline and up to Week 52
|
Baseline and up to Week 52
|
|
|
Change from baseline in glycoalbumin
Tidsram: Baseline and up to Week 52
|
Baseline and up to Week 52
|
|
|
Change from baseline in adiponectin
Tidsram: Baseline and up to Week 52
|
Baseline and up to Week 52
|
|
|
Change from baseline in glucagon
Tidsram: Baseline and up to Week 52
|
Baseline and up to Week 52
|
|
|
Change from baseline in number of units of insulin administered concomitantly
Tidsram: Baseline and up to Week 56
|
Comprehensively assessed by basal insulin daily dose, bolus insulin daily dose and total insulin daily dose.
|
Baseline and up to Week 56
|
|
Change from baseline in body weight
Tidsram: Baseline and up to Week 56
|
Baseline and up to Week 56
|
|
|
Change from baseline in waist circumference
Tidsram: Baseline and up to Week 52
|
Baseline and up to Week 52
|
|
|
Safety assessed by sitting blood pressure
Tidsram: Up to Week 56
|
Up to Week 56
|
|
|
Safety assessed by sitting pulse rate
Tidsram: Up to Week 56
|
Up to Week 56
|
|
|
Safety assessed by standard 12-lead electrocardiogram
Tidsram: Up to Week 56
|
Up to Week 56
|
|
|
Safety assessed by laboratory tests: Hematology
Tidsram: Up to Week 56
|
Up to Week 56
|
|
|
Safety assessed by laboratory tests: Biochemistry
Tidsram: Up to Week 56
|
Up to Week 56
|
|
|
Safety assessed by laboratory tests: Urinalysis
Tidsram: Up to Week 56
|
Up to Week 56
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
29 augusti 2016
Primärt slutförande (Faktisk)
22 juli 2017
Avslutad studie (Faktisk)
15 mars 2018
Studieregistreringsdatum
Först inskickad
27 juli 2016
Först inskickad som uppfyllde QC-kriterierna
7 september 2016
Första postat (Uppskatta)
13 september 2016
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
6 mars 2019
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
5 mars 2019
Senast verifierad
1 mars 2019
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Störningar i glukosmetabolism
- Metaboliska sjukdomar
- Immunsystemets sjukdomar
- Autoimmuna sjukdomar
- Sjukdomar i det endokrina systemet
- Diabetes mellitus
- Diabetes mellitus, typ 1
- Hypoglykemiska medel
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Sodium-Glucose Transporter 2-hämmare
- Ipragliflozin
Andra studie-ID-nummer
- 1941-CL-6002
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development.
Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
Tidsram för IPD-delning
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Kriterier för IPD Sharing Access
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data.
The research proposal is reviewed by an Independent Research Panel.
If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .